Sermorelin Acetate

Sermorelin is the first twenty-nine amino acids of growth hormone–releasing hormone, the signal the hypothalamus sends to the pituitary gland. The natural hormone is forty-four residues long, and the finding that gave this compound its place in research is that the remaining fifteen contribute almost nothing to activity. Everything the receptor needs to recognise is in the opening stretch.

That is a genuinely useful result rather than a piece of trivia. Establishing the minimum sequence that still works tells you which part of a hormone the receptor actually reads, and it produces a far simpler molecule to synthesise and study. Sermorelin has been the reference GHRH analogue since the 1980s for exactly this reason.

It also has a real clinical history. It held a marketing authorisation as a diagnostic agent and in paediatric growth hormone deficiency before being withdrawn commercially — a business decision rather than a safety one. Its pharmacology was therefore examined to a standard rarely reached by research peptides.

• The minimum active sequence: It established that twenty-nine of forty-four residues carry the activity. Questions about which part of a hormone a receptor reads are answered with truncation experiments, and this is one of the cleanest examples.

• Pituitary feedback intact: It prompts the pituitary to release its own growth hormone rather than supplying hormone from outside, so the body's regulatory brakes still operate. Models that need physiological control preserved use this class rather than the hormone itself.

• Short duration as a feature: It clears within minutes. That is a limitation for sustained signalling and an advantage for studying pulses, since the natural hormone is released in bursts rather than continuously.

• A characterised comparator: Because its behaviour has been documented in controlled human studies, newer GHRH analogues are routinely measured against it. Much of its present use is as the baseline other compounds are judged by.

Growth hormone is made and stored in the pituitary, a gland beneath the brain, and released in pulses rather than at a steady rate. Two opposing signals from the hypothalamus above it govern that release: GHRH tells the gland to release, and somatostatin tells it to hold. What arrives in the bloodstream is the result of that push and pull, which is why growth hormone concentrations rise and fall through the day.

Sermorelin engages the receiving end of the first signal — the GHRH receptor on pituitary somatotroph cells. Because the opposing somatostatin signal and the downstream feedback loops are untouched, the pituitary can still refuse. This is the essential distinction between a releasing peptide and administered growth hormone: one works through the control system, the other bypasses it.

The very short duration follows from the sequence itself. Enzymes in blood cut GHRH-type peptides quickly at a known position near the start of the chain, which is why every later analogue in this family is essentially an attempt to protect that site. Sermorelin is the unmodified version, and understanding what it lacks is how the modified ones make sense.

This is one of the better-documented peptides in the catalogue. Sermorelin was an approved medicine, its ability to raise growth hormone in humans was established in controlled studies, and its pharmacokinetics are published. The uncertainty typical of research peptides largely does not apply to the basic question of whether it engages its receptor.

The evidence concerns a diagnostic and paediatric context under medical supervision, and it is supplied for laboratory research only. It held a marketing authorisation and its ability to raise growth hormone in humans was established in controlled studies, which is why it remains the baseline every later GHRH analogue is measured against.

CJC-1295 is the direct descendant: the same twenty-nine-residue fragment with substitutions that protect the site where enzymes cut, and in one form an attachment that keeps it in circulation for days. Reading the two together shows exactly what the modifications were for.

Tesamorelin takes a different route to the same problem, stabilising the full-length hormone rather than shortening it — and is the only member of the family with current marketing authorisation. Compounds such as Ipamorelin act on a separate receptor entirely, which is why the two groups are often examined side by side.